Both US List And Net Drug Price Increases Have Been Substantial, JAMA Study Finds
Executive Summary
A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.
You may also be interested in...
Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says
Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.
The Cost To Bring A New Drug To Market? $1.3bn, JAMA Study Finds
The mean R&D investment required to bring a new drug to market was $1.3bn in a new study estimating pharma R&D costs, lower than the $2.8bn frequently cited from a prior study.
A Muted J.P. Morgan, But The Focus Is Execution – And That's Good News
A lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors, but industry is confidently executing on focused strategies as it welcomes a new decade. The persistent overhang is US drug pricing and political uncertainty.